For the quarter ending 2025-09-30, NMRA made $59,416K in revenue. -$56,731K in net income. Net profit margin of -95.48%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 40,520 | - | ||
| General and administrative | 12,180 | - | ||
| Acquired in-process research and development | 5,000 | - | ||
| Total operating expenses | 57,700 | - | ||
| Loss from operations | -57,700 | -54,040 | ||
| Interest income | 1,685 | - | ||
| Interest expense | 747 | - | ||
| Other expense, net | 7 | -480 | ||
| Interest income, net | - | 1,814 | ||
| Total other income | 945 | 1,334 | ||
| Net loss before income taxes | -56,755 | -52,706 | ||
| Provision for income taxes | 0 | 25 | ||
| Net loss | -56,755 | -52,731 | ||
| Unrealized gain (loss) on marketable securities | 24 | -12 | ||
| Comprehensive loss | -56,731 | -52,743 | ||
| Earnings per share, basic, total | -0.35 | -0.33 | ||
| Earnings per share, diluted, total | -0.35 | -0.33 | ||
| Weighted average number of shares outstanding, basic, total | 161,838,000 | 161,691,000 | ||
| Weighted average number of shares outstanding, diluted, total | 161,838,000 | 161,691,000 | ||
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)